Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Foreign Affairs Discussion Group -- Ignore unavailable to you. Want to Upgrade?

To: stockman_scott who wrote (154636)	12/21/2004 6:49:43 PM
From: goldworldnet	Respond to of 281500

Status of vaccine development for an influenza pandemic A vaccine could reduce the high morbidity and mortality normally associated with influenza pandemics, if available sufficiently early. Significant efforts are needed to expedite vaccine development and thus take advantage of this preventive option. Progress is needed on three fronts. First, countries experiencing outbreaks need to rapidly share human and animal viruses with laboratories in the WHO Global Influenza Surveillance Network. Analysis of these viruses determines the possible need for changes in the prototype vaccine “seed” strains which WHO makes available to the pharmaceutical industry. Second, companies need to engage in research on pandemic vaccine development that includes pilot production of small batches for clinical testing. National licensing agencies in Europe and North America have developed regulatory guidelines for industry. Third, public health agencies need to engage in discussions with pharmaceutical companies to explore areas of common interest in vaccine development and identify areas where support is needed. Since 2003, when two cases of human H5N1 infection occurred in Hong Kong SAR, WHO has worked to identify and resolve problems in order to pave the way for rapid development and production of a pandemic vaccine. Vaccine manufacturers respond to market forces. Companies may be reluctant to produce a vaccine for an event, such as a pandemic, that cannot be predicted with any certainty and might not be caused by currently circulating strains. Some uncertainty has also centered on rights to use the special technique of reverse genetics, a patented procedure, that is needed to produce the prototype “seed” vaccine against H5N1. At the beginning of April 2004, WHO made the prototype seed strain for an H5N1 vaccine available to manufacturers. To date, only two of the world’s roughly 12 major companies producing influenza vaccines have taken work on a pandemic vaccine significantly forward. These two companies, Aventis Pasteur Inc. and Chiron Corp., both located in the USA, have produced small batches of vaccine for use in clinical trials. These trials, which require several months for the compilation and analysis of data, are needed to fine-tune vaccine composition, test safety, and meet other licensing requirements. Trials are not expected to begin before year-end. who.int * * *